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Background: ATL-146e protects the spinal cord from ischemia/reperfusion injury, presumably via adenosine A2A
receptor activation, but this relationship remains unproven. We hypothesized that spinal cord functional and cytoarchi-
tectural preservation from ATL-146e would be lost with simultaneous administration of the specific adenosine A2A
antagonist ZM241385 (ZM), thus proving that adenosine A2A receptor activation is responsible for the protective effects
of this compound.
Methods:NewZealandWhite rabbits underwent 45minutes of infrarenal aortic cross-clamping. Groups (n 10) included
sham, ischemia, ischemia plus ATL-146e (ATL-146E), ischemia plus ZM, or ischemia with both compounds (agonist-
antagonist). Tarlov scores were recorded every 12 hours. After 48 hours, the spinal cord was fixed for histology and
microtubule-associated protein 2 immunohistochemistry.
Results: Tarlov scores at 48 hours were significantly better in the sham and ATL-146E groups (5.0 and 3.9, respectively)
compared with the other three groups (all <1.3; P < .001). On hematoxylin and eosin, neuronal viability was higher in
the sham, ATL-146E, and agonist-antagonist groups compared with the control and ZM groups (P< .05). Microtubule-
associated protein 2 expression was preserved in the sham and ATL-146E groups but was lost in the ATL  ZM,
ZM241385, and control groups.
Conclusions: ATL-146e preserves the spinal cord in terms of both cytoarchitecture and function after reperfusion of the
ischemic spinal cord, but this preservation is not completely blocked by competitive adenosine A2A receptor antagonism.
Although ATL-146e does seem to partially function through activation of the adenosine A2A receptor, the neuroprotec-
tive mechanism may not be limited to this particular receptor. ( J Vasc Surg 2006;44:392-7.)
Clinical Relevance:Paraplegia remains a real and devastating complication of vascular procedures that involve the thoracic
aorta. Pharmacologic intervention has not yet had the proven success of other surgical adjuncts in limiting this
complication, but treatment with adenosine analogues at reperfusion has shown promise in animal models. This study
examined the specificity of the neuroprotective qualities of an adenosine receptor agonist in the setting of spinal cord
ischemia/reperfusion injury with the ultimate goal of preventing neurologic complications in this specific subset of
vascular patients.Paraplegia is a significant and devastating complication
for patients undergoing aortic aneurysm repair. This is
especially true in higher-risk procedures of the thoracic
aorta and in patients with previous abdominal aortic sur-
gery. Paraplegia rates can range from 4% to 21%, depending
on the location and extent of the aortic pathology.1-4
Pharmacologic protection of the spinal cord during aortic
surgery has not enjoyed the success that cerebrospinal fluid
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392drainage, local hypothermia, and distal perfusion have
more recently demonstrated.5-7 However, research has
demonstrated promising success with some medications in
multiple animal models of spinal cord ischemia/reperfu-
sion.8
ATL-146e is among the pharmacologic interventions
demonstrating promise. ATL-146e presumably works
through adenosine A2A receptor activation on several dif-
ferent cell types, most notably smooth muscle cells and
neutrophils.9,10 Although the mechanism of this drug’s
function has been proven in other organ models of isch-
emia/reperfusion, the neuroprotective effect during spinal
cord ischemia and reperfusion has not been fully eluci-
dated. The mechanism can possibly be proven by blocking
adenosine A2A receptor activation with an antagonist spe-
cific to the adenosine A2A receptor. ZM241385 (ZM) has
been used in drug development to exclusively block the
effects of A2A activation.
11-14 ZM is a competitive antago-
nist that requires a higher molar concentration to block the
agonist’s effects. If ATL-146e does indeed work through
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tive effects of the drug would be lost when combined with
a higher dose of ZM.
Furthermore, previous studies have shown highly vari-
able results in terms of spinal cord cytoarchitectural
changes after spinal cord ischemia/reperfusion in animal
models. The problem remains that many studies are re-
stricted to short reperfusion periods for debilitated animals,
but the neuronal degeneration and the ability to identify
this degeneration may progress for 7 days or longer. Pres-
ently, our institutional vivarium policy limits our reperfu-
sion times to 48 hours for animals with complete hind-limb
paralysis and an inability to void, so better markers of early
cytoarchitectural changes must be identified. Neuronal vi-
ability alone, in our experience, is probably too limited in
this time frame. Microtubule-associated protein (MAP)-2
has been shown in neuronal ischemia to be a very sensitive
early marker of ischemic insult.15 The addition of MAP-2
expression may be a superior marker of cellular damage
compared with our previously described neuronal viability
alone.
The aim of this study was to establish that the effects of
ATL-146e are specific to adenosine A2A activation. We
hypothesized that protection of the ischemic spinal cord
with ATL-146e requires adenosine A2A activation and that
the addition of MAP-2 better evaluates early ischemia/
reperfusion spinal cord injury.
METHODS
Procedures. All protocols were reviewed and ap-
proved by the Animal Care and Use Committee of the
University of Virginia. All animals received humane care in
compliance with the Guide for the Care and Use of Labora-
tory Animals, as described by the Institute of Laboratory
Animal Resources, Commission on Life Sciences, National
Research Council (1996).
The study used mature New ZealandWhite rabbits in a
model of normothermic spinal cord ischemia/reperfusion.
After induction and endotracheal intubation, they were
ventilated with a volume ventilator at a tidal volume of 20
mL and a rate of 25 breaths/min. Throughout the proce-
dure, they received vaporized halothane, which was titrated
to appropriate sedation. Arterial catheters were placed in
the ears for blood pressure monitoring, and the marginal
ear vein was accessed for delivery of both normal saline and
any intravenous therapy.
The animals were divided into five groups: sham, isch-
emic controls, ATL-146E treatment, ZM treatment, and
ATL  ZM. Sham animals (n  8) underwent laparotomy
with an open abdomen for 45 minutes before closure.
Ischemia-reperfusion animals (IR; n  10) underwent lap-
arotomy with 45minutes of ischemia by cross-clamping the
infrarenal aorta and inferior vena cava in addition to cross-
clamping both vessels at the iliac bifurcation to ensure no
backflow perfusion. The final three groups underwent pro-
cedures identical to the control except that ATL-146e–
treated animals (ATL-146E; n  10) received 0.06 g ·
kg1 · min1 of ATL-146e for 3 hours beginning 10minutes before reperfusion, antagonist animals (ZM; n 
10) received 10 times the molar equivalent (0.42 g · kg1
· min1) of ZM for 3 hours, and the combined-therapy
group (agonist-antagonist; n  10) received both of these
drugs at the previous dose and rate, simultaneously. Both
drugs were given by using a Harvard microinfusion pump
(Harvard Apparatus, Holliston, Mass).
The animals recovered until they were able to indepen-
dently lift their heads. They survived for 48 hours under
close supervision. All animals that were unable to sit up
independently received a bolus of intravenous fluids twice
per day and were hand-fed. At 48 hours, all animals were
again anesthetized and perfusion-fixed with formalin. Spi-
nal cords were harvested and placed in formalin for histol-
ogy and immunohistochemistry.
Function. The Tarlov scale was used to assess func-
tional outcomes at 12, 24, 36, and 48 hours. The Tarlov
scale grades the animals according to their ability to move,
sit, and hop. A score of 0 indicates complete paraplegia with
no movement in the hind limbs. A score of 1 indicates that
the animal has some hind limb movement. A score of 2
means the animal can sit with assistance, whereas 3 means it
can sit on its own. A score of 4 means the animal has a weak
hop, and 5 means the animal has a normal hop. The
reported scores were graded by a blinded observer with no
tie to the project.
Neuronal viability. Fixed spinal cords were sectioned
into 5-m sections. Eight to 12 sections of each spinal cord
were stained with hematoxylin and eosin. These sections
were graded by a blinded observer who counted the num-
ber of viable motor neurons in each high-power field.
Neurons were considered nonviable on the basis of loss of
nuclear structure, cellular retraction from the surrounding
tissue, and loss of cellular architecture. Neuronal viability
was based on the number of viable neurons per high-power
field.
MAP-2 immunohistochemistry. Lumbar spinal
cords were embedded in paraffin, and transverse sections
were cut with a microtome. Ten-micrometer sections were
mounted on slides and deparaffinized in xylenes and pro-
gressive alcohol rinses. In preparation for immunocyto-
chemistry, sections were processed with a temperature-
controlled microwave antigen-retrieval approach described
previously in detail.16 Endogenous peroxidase was blocked
by incubation in a solution of 1.65% hydrogen peroxide in
0.025% Triton X in Tris-buffered saline (TBS). Sections
were then incubated overnight in mouse anti–MAP-2 an-
tibody (clone HM-2; Sigma-Aldrich Co, St Louis, Mo) at a
dilution of 1:100 in TBS with 1% bovine serum albumin.
The following day, sections were rinsed in TBS/Triton X
and then incubated for 2 hours in biotinylated anti-mouse
immunoglobulin G (1:200; Vector, Burlingame, Calif) in
TBS with 1% bovine serum albumin. After incubation in an
avidin-biotin-peroxidase complex (ABC standard Elite kit;
Vector; dilution, 1:100), sections were processed for visu-
alization of the immunohistochemical complex by using
0.05% diaminobenzidine (Sigma-Aldrich) and 0.01% hy-
drogen peroxide. Once the sections were stained, they were
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percentage of gray matter staining for MAP-2 was ob-
tained. Thus, MAP-2 is expressed as a percentage of stain-
ing per section of gray matter.
Statistics. The five groups were analyzed by using
analysis of variance with a Bonferroni multiple comparison
test to determine significant differences. Assumptions were
tested, and nonparametric test results verified the results of
the analysis of variance. The statistics for this study were
performed by an independent statistician.
RESULTS
Functional outcomes. Tarlov scores at 12 hours were
as follows: sham, 5 0; IR, 0.5 0.40; ATL-146E, 3.8
0.44; ZM, 0.9 0.43; and agonist-antagonist, 1.3 0.54.
Tarlov scores at 24 hours were as follows: sham, 4.9 
0.13; IR, 0.5  0.40; ATL-146E, 3.9  0.38; ZM, 1.0 
0.45; and agonist-antagonist, 1.4  0.52. Tarlov scores at
36 hours were as follows: sham, 5  0; IR, 0.6  0.43;
ATL-146E, 3.8  0.49; ZM, 0.9  0.42; and agonist-
antagonist, 1.4  0.48. Tarlov scores at 48 hours were as
follows: sham, 5  0; IR, 0.5  0.40; ATL-146E, 3.9 
0.48; ZM, 0.9 0.41; and agonist-antagonist, 1.3 0.47.
At all time points, both the sham and ATL-146E groups
had significantly better function compared with the IR,
ZM, and agonist-antagonist groups (each P .001). These
findings are depicted graphically in Fig 1.
Neuronal viability. Sham animals had the highest
neuronal viability, with 2.6  0.09 per high-power field.
ATL-146E–treated animals had the next highest neuronal
viability, with 1.84  0.04 per high-power field, closely
followed by the agonist-antagonist group, with 1.833 
0.05 per high-power field. The worst two neuronal viabil-
ities were found in ZM (1.00 0.05) and control (1.025
0.03) animals. Sham, ATL-146E, and agonist-antagonist
animals were all significantly better than both ZM and IR
animals (P  .01). Neuronal viability outcomes are pre-
sented graphically in Fig 2.
MAP-2 immunohistochemistry. MAP-2 expression
Fig 1. Functional outcomes. Hind-limb function was signifi-
cantly preserved in the sham and ATL-146E groups compared
with the other three groups at every time point (*P  .01 vs
control, ZM, and agonist-antagonist, A and Z).was significantly preserved in sham animals compared withall other groups (all P  .01). MAP-2 expression in ATL-
146E animals was significantly better than in the ZM and
IR groups, with a trend toward better preservation than in
the agonist-antagonist group (P  .1). MAP-2 expression
was statistically similar among agonist-antagonist, ZM, and
IR animals. Representative sections are shown in Fig 3, and
MAP-2 expression is quantified in Fig 4.
DISCUSSION
Transient occlusion of the thoracoabdominal aorta
during vascular surgery carries a significant risk for postpro-
cedural neurologic deficit. Recent studies in thoracoab-
dominal aneurysms suggest that this risk can be minimized
with several modalities of spinal cord preservation, includ-
ing cerebrospinal fluid drainage via the lumbar drain, re-
Fig 2. Neuronal viability. Neuronal viability by hematoxylin and
eosin demonstrated significant preservation of neuronal cytoarchi-
tecture per high-power field in the sham group and both groups
receiving ATL-146E (*P  .01 vs IR and ZM).
Fig 3. Microtubule-associated protein (MAP)-2. These pho-
tomicrographs depict theMAP-2 expression of spinal cord sections
after ischemia/reperfusion. (A) and (B) depict the sham and
ATL-146E groups, respectively, with preservation of the filamen-
tous structures within the gray matter. (C) depicts the combined-
therapy group, with some background staining but with complete
loss of the neural filaments. Finally, (D) depicts the control and
ZM groups, with complete loss of even background staining for
MAP-2.gional hypothermia, and left heart bypass with distal perfu-
vs ZM
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neurologic outcomes in many patients, the extra procedure
adds risks of additional complications, and they are not
uniformly successful. A pharmacologic means of protecting
the spinal cord from ischemia/reperfusion injury may ob-
viate the need for more invasive strategies.
We have previously shown functional preservation of
the spinal cord after ischemic injury with the use of hypo-
thermic adenosine given in a retrograde venous fashion
during ischemia.17-21 The instability of adenosine at body
temperature and the interruption of arterial flow to the
ischemic tissue necessitated retrograde delivery during the
ischemic period. These studies demonstrated significant
functional improvement of the spinal cord with this retro-
grade delivery of cold adenosine during ischemia. How-
ever, the significant effort required for spinal cord protec-
tion via this route limits its potential clinical utility.
Recent studies have indicated that adenosine’s effects
are mediated through at least four defined receptors.9 One
such receptor, the adenosine A2A receptor, seems to be
responsible for many of the anti-inflammatory properties of
Fig 4. Microtubule-associated protein (MAP)-2. MAP-
matter stained. *P  .01 vs all other groups; **P  .01adenosine. The adenosine A2A receptor is predominantlyexpressed on inflammatory cells and vascular smooth mus-
cle. Both of these cell types are thought to play roles in the
pathogenesis of injury after the reperfusion of ischemic
tissues. Activation of the adenosine A2A receptor can impair
the inflammatory process and, at higher doses, lead to
vasodilatation.
ATL-146e is a selective A2A-receptor agonist with
nominal cross-reactivity with A3 receptors.
22 ATL-146e
has been shown in previous studies to preserve spinal cord
function in models of both ischemic and traumatic spinal
cord injury.23-26 Although activation of the adenosine A2A
receptor was thought to be responsible for these protective
actions, to our knowledge no study to date has addressed
this mechanistic presumption.
In this study, we administered a competitive adenosine
A2A antagonist, ZM, to test whether competitive antago-
nism of the adenosine A2A receptor blocks the neuropro-
tective effect of ATL-146e. A ZM dose of 10 times the
concentration of ATL-146e was used to maximize receptor
saturation by the antagonist. The neurobehavioral results
of this study demonstrate that ATL-146e–mediated pres-
unohistochemistry is depicted as the percentage of gray
and ischemia/reperfusion.2 immervation of spinal cord function is lost with competitive
JOURNAL OF VASCULAR SURGERY
August 2006396 Reece et alreceptor blockade by ZM. Additionally, ZM alone did not
result in further deterioration of function compared with
control, thus implying that endogenous adenosine A2A
receptor activation plays little or no role in innate functional
protection from this mode of ischemic injury.
In terms of cytoarchitecture, our study presents some
confounding results. Gray matter MAP-2 staining, indicat-
ing ischemic cytoskeletal injury, was significantly dimin-
ished in the IR control group and the ZM group compared
with the ATL-146e and sham groups. MAP-2 staining in
the agonist-antagonist group tended to be worse than the
MAP-2 staining in the ATL-146e group, but with only a
trend statistically (P  .1).
With respect to the hematoxylin and eosin neuronal
viability data, the sham, ATL-146e, and agonist-antagonist
groups demonstrated preserved neuronal viability com-
pared with the ischemia/reperfusion control and ZM
groups. As with the MAP-2 data, coadministration of an-
tagonist with agonist failed to completely block the effect of
ATL-146e on neuronal viability.
We suspect that the disconnect between the functional
and the cytoarchitectural outcomes in the agonist-antago-
nist group may be due to three factors. First, the coadmin-
istration of agonists and antagonists causes a rightward shift
of the dose-response curve of the agonist, thus limiting, but
not eliminating, the effects of the agonist. Therefore, the
combination of ATL-146e and the antagonist ZMmay not
result in complete blockade of ATL-146e effects. Second,
although ATL-146e is a selective A2A receptor agonist, its
effects are not limited to the adenosine A2A receptor only.
Thus, competitive blockade of the adenosine A2A receptor
would not completely block the actions of ATL-146e.
ATL-146e is known to have limited activity at the adeno-
sine A3 receptor as well,
22 and the adenosine A3 receptor
has been shown to mediate ischemic preconditioning in
isolated heart models of ischemia/reperfusion.26-28 The
low-level activation of the A3 receptor could account for
the incomplete blockade of the protective cytoarchitectural
effects seen in our study with coadministration of an A2A
competitive antagonist. The third factor affecting interpre-
tation of our results is that, in our ischemia/reperfusion
model, functional preservation occurs before cytoarchitec-
tural changes. More specifically, in previous data, the neu-
robehavioral effects of ATL-146e were detected at earlier
time points than protective effects on cytoarchitecture,
which can take a week or longer to manifest.29 On the basis
of that study, we would expect the functional deficit to
predict eventual cellular structure deterioration. Thus, in
terms of this study, it may be that the process of cytoarchi-
tectural degeneration was prolonged by administration of
an antagonist and extended beyond the survival time used
in the study design. Therefore, the divergence between
functional and cytoarchitectural outcomes in this studymay
simply reflect a dampened neuronal response to ATL-146e
in combination with ZM that still ultimately results in
neuronal death.
This study raises intriguing questions about the poten-
tial contribution of A3 receptor activation in adenosine-mediated spinal cord protection. Although adenosine A2A
receptor activation is the principal player in the attenuation
of spinal cord ischemia/reperfusion injury, we cannot ex-
clude a smaller contribution by adenosine A3 receptor
agonism. The study also builds onmultiple previous studies
to provide further evidence that systemic delivery of ATL-
146e preserves spinal cord function and neuronal viability
after ischemia/reperfusion injury. Clinical trials using this
compound in this type of injury are imminent. To date, to
our knowledge, no known adverse effects have been iden-
tified with the use of ATL-146e in animals or humans.
Because ATL-146e is now in clinical trials as a cardiac
imaging agent, it will soon be eligible for trials in other
disease paradigms, including spinal cord injury and spinal
cord ischemia/reperfusion.
This study supports our hypothesis that treatment of
the ischemic spinal cord at reperfusion with ATL-146e can
attenuate injury, with the activation of the adenosine A2A
receptor playing a significant, but possibly not exclusive,
role in its protective mechanism. In conclusion, ATL-146e
treatment preserves spinal cord function and cytoarchitec-
ture after spinal cord ischemia/reperfusion and may pro-
vide another option for neuroprotection in patients under-
going risky vascular procedures in the future.
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